Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer
Latest Information Update: 29 Mar 2024
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Adverse reactions
- 26 Mar 2024 Status changed from active, no longer recruiting to completed.
- 15 Aug 2022 Planned End Date changed from 1 Jun 2022 to 31 Dec 2023.
- 27 Dec 2021 Planned End Date changed from 1 Nov 2021 to 1 Jun 2022.